Conditions: Solid Tumor, Adult; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Endometrial Cancer; Peritoneal Cancer; Solid Tumor
Interventions: Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide); Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
Sponsor: Bio-Path Holdings, Inc.
**RECRUITING NOW**
Interventions: Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide); Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
Sponsor: Bio-Path Holdings, Inc.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
